Pacific Biosciences of California Profit Margin

Pacific Biosciences of California (PACB) currently reports a profit margin of -81.31% as of September 2026. That compares with -325.02% in the prior-year period — up 75.0% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Pacific Biosciences of California's profit margin history and peer comparisons.

Pacific Biosciences of California's profit margin increased from -325.02% to -81.31% — a 75.0% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pacific Biosciences of California's profit margin of -81.31% is lower than the Healthcare sector average of 9.48%. That is roughly 957.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Pacific Biosciences of California's current -81.31% should be judged against Healthcare norms (sector average: 9.48%) and against PACB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -81.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Pacific Biosciences of California, and consider following PACB for alerts when major investors trade the stock.